Navigation Links
New Study Links dLife to Increased Rx Drug Usage Among Diabetes Consumers
Date:3/3/2010

WESTPORT, Conn., March 3 /PRNewswire-USNewswire/ -- A new study analyzing patient-level prescription data clearly demonstrates that dLife consumers take immediate and deeper action in treating their diabetes and co-morbid conditions after becoming engaged with dLife.  The study also confirms that dLife users test their blood sugar and take medications at a higher rate than non-dLife users.

In the study conducted by Crossix Solutions, Inc. ("Crossix"), the Rx purchasing habits of dLife members were analyzed prior to and after engaging with dLife.  In the period immediately following their engagement, as compared to the general population, more dLife diabetes consumers:

  • Begin Rx treatment for diabetes (+1600%)
  • Add insulin to their current treatment (+125%)
  • Switch from generic meds to branded (+50%)
  • Start test strip use (+700%)
  • Start on cholesterol (+160%) and high blood pressure meds (+150%)

Also, dLife diabetes consumers have higher adherence with their Rx purchase behavior demonstrating higher utilization of insulin (+9%) and test strip usage (+21%) in the post-engagement period.

"We have repeatedly found through our A&U studies over the years that dLife both attracts active health managers and also creates them.  And now we have the 3rd party Rx data to support it," says Howard Steinberg, CEO & Founder of dLife.  "There are so many who know they should be doing more but until they find dLife they don't know how to get there or can't find the motivation to start.  Across our media, everyone can find information they understand and enjoy, educational tools that truly help them learn, and inspiration from others to make lasting changes in their daily diabetes routine.  More aggressive therapeutic management of diabetes and co-morbid conditions is often as simple as lifestyle adjustments."

dLife, the only multimedia network serving the diabetes community, touches over 5 million active diabetes managers through the award-winning television show, dLifeTV, the only lifestyle TV series for people with diabetes, and dLife.com, attracting 1 million diabetes visitors every month making it the leading online destination for diabetes information, inspiration, and connection.

About dLife

dLife is the only multimedia network serving the diabetes community. Its award-winning multimedia outlets include dLifeTV, the only lifestyle TV series for people with diabetes, airing every Sunday on CNBC at 7:00PM ET and 4:00PM PT. dLife.com, with over 80,000 pages of superior content, 9,000 diabetic recipes, and over 400 videos is the leading online destination for diabetes information, inspiration, and connection. The dLife network also includes dLifeRadio, featuring the dLife Diabetes Minute, heard on stations around the country and on XM Satellite Radio; dLifeDirect, the only diabetes cooperative direct-mail program; professional programs; and more.

About Crossix

Crossix Solutions, Inc. was founded in 2004 by a team that combines pharmaceutical and marketing experience with technology and analytical expertise. Their patent-pending, privacy-safe Crossix Scoreboard™ utilizes patient level Rx data from a proprietary network of pharmacies, PBMs and other healthcare organizations to analyze and optimize the impact of consumer marketing and patient adherence programs.

SOURCE dLife

Back to top
'/>"/>
SOURCE dLife
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and ... This is in conjunction with this morning,s announcement of ... Thrombosis and Nutritional Insufficiency businesses. Cardinal Health ... operations will be at the bottom of its previous ...
(Date:4/18/2017)... DALLAS , April 18, 2017 Viverae ... proud to announce the integration of IBM ® ... platform to deliver targeted communications for a personalized experience. ... meaningful actions on their health in real time. The ... that matter most to members, wherever they are in ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ... announces Mirroring360 Pro . This new addition to the Mirroring360 product family ... education and business. , Mirroring360 Pro enables educators, business professionals and individuals to ...
(Date:4/25/2017)... , ... April 25, 2017 , ... A stressful work ... work can also decrease overall productivity and performance in the workplace. The goal of ... During the last few weeks of April, Clearview Resolution Services will be shutting down ...
(Date:4/25/2017)... ... 25, 2017 , ... The doctors at Wall Centre Dental are now expanding ... and require sedation to receive dental care. The doctors offer three treatment options to ... cleanings to oral surgery, at their dental office in Vancouver. Wall Centre Dental is ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... , ... April 25, 2017 , ... Buyers and sellers ... users to dispensaries and head shops –can’t help but be heartened by the industry’s ... tell-tale cannabis odor aptly described as “skunk smell.” At last they can simply, ...
Breaking Medicine News(10 mins):